Metastatic Prostate Cancer Pipeline Outlook 2025

Strategic Insights -

The Metastatic Prostate Cancer pipeline has witnessed considerable growth in recent years, with numerous companies and research institutions working to develop innovative treatments. DelveInsight's report provides comprehensive insights into the Metastatic Prostate Cancer pipeline landscape, covering 80+ companies and 85+ pipeline drugs.

Metastatic Prostate Cancer is a life-threatening disease that affects thousands of men worldwide. The pipeline has seen an increase in innovative treatments, including targeted therapies and immunotherapies. Key players such as Merck, AstraZeneca, and Syntrix Pharmaceuticals are actively developing treatments for Metastatic Prostate Cancer.

Key Takeaways:

  • On 22 August 2025, Bayer conducted a study to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer.
  • On 22 August 2025, Novartis Pharmaceuticals announced a study to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with mHSPC.
  • DelveInsight's Metastatic Prostate Cancer Pipeline report depicts a robust space with 80+ active players working to develop 85+ pipeline therapies for Metastatic Prostate Cancer treatment.
  • The leading Metastatic Prostate Cancer Companies such as Merck, AstraZeneca, Syntrix Pharmaceuticals, Cardiff Oncology, Janux Therapeutics, ORIC Pharmaceuticals, Inc, Lantheus, Eli Lilly and Company, Madison Vaccines, Exelixis, Laekna Therapeutics, Regeneron Pharmaceuticals, Zenith Epigenetics, Phosplatin Therapeutics, MacroGenics, Modra Pharmaceuticals, RedHill Biopharma, DexTech Medical, Debiopharm, Astellas Pharma, Arvinas, Orion Corporation, CellCentric, Karyopharm Therapeutics, Corcept Therapeutics, OncoC4, Inmune Bio, Celcuity and others.
  • Promising Metastatic Prostate Cancer Pipeline Therapies such as Enzalutamide, Cabazitaxel, Ifinatamab Deruxtecan, MK-5684, Aflibercept, HLD-0915, Prednisone, Quinacrine, SR31747A anad others.

Statistics:

  • Approximately 1126 patients will be randomized in the study evaluating 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with mHSPC.
  • As of 31-Jan-2024, 1144 participants have been enrolled in 20 countries in the same study.
  • The Metastatic Prostate Cancer pipeline has 80+ active players working to develop 85+ pipeline therapies for Metastatic Prostate Cancer treatment.

Sources:

  • DelveInsight's Metastatic Prostate Cancer Pipeline Insight Report, 2025
  • Bayer's study on darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer, published on August 22, 2025
  • Novartis Pharmaceuticals' study on the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with mHSPC, published on August 22, 2025
  • Mentioned press releases